New hope for aggressive breast cancer: targeted drug combo shows promise in early trial
NCT ID NCT06797635
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants will receive different combinations of these drugs before surgery, and researchers will check how many have no cancer cells left after surgery. The study also monitors safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Patritumab deruxtecan (a targeted antibody-drug conjugate) plus pembrolizumab (an immunotherapy) and chemotherapy (carboplatin, paclitaxel, doxorubicin)
What this could lead to
If successful, this could lead to a more effective treatment before surgery for high-risk early-stage breast cancer, potentially increasing the chance of eliminating all cancer cells.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not apply to everyone. The combination of drugs can cause serious side effects, including lung inflammation and immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 2401)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 1703)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Reina Sofia ( Site 1702)
RECRUITINGCórdoba, 14004, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0022)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
RECRUITINGBadalona, Catalonia, 08916, Spain
Contact Phone: •••-•••-••••
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
RECRUITINGBillings, Montana, 59102, United States
Contact Phone: •••-•••-••••
-
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
RECRUITINGTaipei, 112, Taiwan
Contact Phone: •••-•••-••••
-
National Cheng Kung University Hospital ( Site 2503)
RECRUITINGTainan, 704, Taiwan
Contact Phone: •••-•••-••••
-
Northwest Cancer Specialists (Compass Oncology) ( Site 8003)
RECRUITINGTigard, Oregon, 97223, United States
Contact Phone: •••-•••-••••
-
Orchard Healthcare Research Inc. ( Site 0006)
RECRUITINGSkokie, Illinois, 60077, United States
Contact Phone: •••-•••-••••
-
SCRI Oncology Partners ( Site 7000)
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Seoul National University Hospital ( Site 2400)
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 2402)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Taichung Veterans General Hospital ( Site 2502)
RECRUITINGTaichung, 407, Taiwan
Contact Phone: •••-•••-••••
-
Texas Oncology - DFW ( Site 8000)
RECRUITINGDallas, Texas, 75246, United States
Contact Phone: •••-•••-••••
-
UCLA Hematology/Oncology - Parkside ( Site 0021)
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-••••
-
Virginia Oncology Associates (VOA) ( Site 8001)
RECRUITINGNorfolk, Virginia, 23502, United States
Contact Phone: •••-•••-••••